KBP Biosciences Raises $76 Million in Series A Financing and Appoints Brian P. McVeigh as Chief Executive Officer– Established China Biotechnology Company with Deep R&D; Pipeline Opens Global Headquarters in the United States –
– Proceeds will also advance clinical development of lead candidate, KBP-5074, through Phase 2b trials for cardiovascular disease –
JINAN, China & PHILADELPHIA, January 5, 2018-- KBP Biosciences, a private clinical-stage biotechnology company dedicated to the research, development and commercialization of innovative medicines in areas of unmet medical need, today announced the closing of a $76 million Series A financing.